Efficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-Analysis

Clicks: 1
ID: 313945
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #75 of 81 articles by views in Aesthetic Surgery Journal Open Forum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Upper Facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment, yet comprehensive synthesized evidence is limited. Objectives To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP and ClinicalTrials.gov were performed to identify RCTs evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs) and headaches. Results Three RCTs (n=704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared to placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89–46.73), HFLs (RR 19.17, 95% CI: 9.23–39.80), and LCLs (RR 11.68, 95% CI: 7.49–18.20), all p<0.00001. A ≥2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all p<0.00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11–2.46, p<0.00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, p=0.03). There was no significant difference in TEAEs and headaches from placebo. Conclusions IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile versus placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation.
Reference Key
openalex_W7160692345 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dr Muhammad Tayyab Azam, Muhammad Hussain Azam, Muhammad Hassan Azam, Shahzad Ashraf, Muhammad Arif Khan, Hasibullah Aminpoor
Journal Aesthetic Surgery Journal Open Forum
Year 2026
DOI
10.1093/asjof/ojag085
URL
https://doi.org/10.1093/asjof/ojag085
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.